Dopamine receptors and the pharmacogenetics of side-effects of stimulant treatment for attention-deficit/hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 23, Issue 6, 2013, Pages 423-425

  Levy, Florence ^a   Wimalaweera, Subodha ^b   Moul, Caroline ^b   Brennan, John ^a   Dadds, Mark R ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CLONIDINE; DEXAMPHETAMINE; DNA; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; METHYLPHENIDATE;

ADOLESCENT; ALLELE; ATTENTION DEFICIT DISORDER; CAUCASIAN; CHILD; DISEASE SEVERITY; DNA EXTRACTION; DSM-IV; EDITORIAL; FOLLOW UP; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; NAUSEA; PHARMACOGENETICS; PRESCHOOL CHILD; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL WITHDRAWAL; RECEPTOR GENE; SALIVA ANALYSIS; SCHOOL CHILD; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; PHARMACOGENETICS; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D1;

EID: 84882773367     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2013.0006     Document Type: Editorial

References (11)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994
2. Arnsten AFT: Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: An important role for prefrontal cortex dysfunction. CNS Drugs 23:33-41, 2009
3. Barkley RA, McMurray MB, Edelbrock CS, Robbins K: Side effects of methylphenidate in children with attention deficit hyperactivity disorder: A systemic placebo-controlled evaluation. Pediatrics 86:84-87, 1990
4. Bobb AJ, Addington AM, Sidransky E, Gornick MC, Lerch JP, Greenstein DK, Clasen LS, Sharp WS, Inoff-Germain G, Wavrant-De Vrieze F, Arcos-Burgos M, Straub RE, Hardy JA, Castellanos FX, Rapoport JL: Support for association between ADHD and two candidate genes: NET1 and DRD1. Am J Med Genet B Neuropsychiatr Genet 134:67-72, 2005
5. Froehlich TE, McGough JJ, Stein MA: Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS Drugs 24:99-117, 2010
6. Huang W, Ma JZ, Payne TJ, Beuten J, Dupont RT, Li MD: Significant association of DRD1 with nicotine dependence. Hum Genet 123:133-140, 2008
7. Lai IC, Mo GH, Chen ML, Wang YC, Chen JY, Liao DL, Bai YM, Lin CC, Chen TT, Liou YJ: Analysis of genetic variations in the dopamine D1 receptor (DRD1) gene and antipsychotics-induced tardive dyskinesia in schizophrenia. European J Clin Pharmacol 67:383-388, 2011
8. Lewis DA, Gonzalez-Burgos G: Physiologically based treatment interventions in schizophrenia. Nat Med 12:1016-1022, 2006
9. Potkin SG, Basile VS, Jin Y, Masellis M, Badri F, Keator D, Wu JC, Alva G, Carreon DT, Bunney WE Jr, Fallon JH, Kennedy JL: D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry 8:109-113, 2003
10. Sawaguchi T, Goldman-Rakic PS: The role of D1-dopamine receptors in working memory: Local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed response task. J Neurophysiol 71:351-358, 1994
11. Seamans JK, Yang CR: The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74:1-58, 2004